Chongqing Genrix Biopharmaceutical Co., Ltd.

SHSE:688443 Stock Report

Market Cap: CN¥10.0b

Chongqing Genrix Biopharmaceutical Balance Sheet Health

Financial Health criteria checks 4/6

Chongqing Genrix Biopharmaceutical has a total shareholder equity of CN¥2.4B and total debt of CN¥748.0M, which brings its debt-to-equity ratio to 31.8%. Its total assets and total liabilities are CN¥3.3B and CN¥927.2M respectively.

Key information

31.8%

Debt to equity ratio

CN¥748.03m

Debt

Interest coverage ration/a
CashCN¥2.56b
EquityCN¥2.35b
Total liabilitiesCN¥927.17m
Total assetsCN¥3.28b

Recent financial health updates

Recent updates

Here's Why Chongqing Genrix Biopharmaceutical (SHSE:688443) Can Manage Its Debt Despite Losing Money

Oct 23
Here's Why Chongqing Genrix Biopharmaceutical (SHSE:688443) Can Manage Its Debt Despite Losing Money

Despite Lacking Profits Chongqing Genrix Biopharmaceutical (SHSE:688443) Seems To Be On Top Of Its Debt

Jun 27
Despite Lacking Profits Chongqing Genrix Biopharmaceutical (SHSE:688443) Seems To Be On Top Of Its Debt

Financial Position Analysis

Short Term Liabilities: 688443's short term assets (CN¥2.7B) exceed its short term liabilities (CN¥144.3M).

Long Term Liabilities: 688443's short term assets (CN¥2.7B) exceed its long term liabilities (CN¥782.9M).


Debt to Equity History and Analysis

Debt Level: 688443 has more cash than its total debt.

Reducing Debt: Insufficient data to determine if 688443's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 688443 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 688443 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 03:01
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chongqing Genrix Biopharmaceutical Co., Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peng ZouChina International Capital Corporation Limited
null nullChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited